Topics:

All Content

The topic of obesity and its effect on cancer risk and subsequent treatment was discussed in detail at this year's Oncology Nursing Society annual meeting in Orlando, Florida.

T cells that express a HER2-specific chimeric antigen receptor showed promise as a treatment for HER-2 positive sarcoma in a small phase I/II trial.

A new population-based study has found that patients with thyroid cancer who are treated with radioactive iodine therapy are at increased risk for developing salivary cancer as a second malignancy.

Patients with lung cancer are increasingly receiving targeted therapies that induce complete disease remissions, but they can also develop resistance to these drugs. New efforts are now underway to discover and develop new options for patients experiencing drug resistance.

For patients with advanced follicular lymphoma, a treatment strategy of rituximab induction was the most cost-effective approach compared with watch and wait.

A recent study found that women diagnosed with breast cancer are at increased risk for developing thyroid cancer, prompting the authors to encourage regular screening for the disease in breast cancer survivors.

As part of our coverage of the ONS Annual Congress, we discuss some of the unique psychosocial challenges faced by young adults with cancer.

Pfizer announced that the phase III trial of palbociclib was stopped early after meeting its primary endpoint of improved progression-free survival in women with HR–positive, HER2-negative metastatic breast cancer.

As part of our coverage of the ONS Annual Congress, we are discussing the oncology nurse's role in distress screening in cancer patients.

Patients with early-stage Hodgkin lymphoma who have a negative PET finding after 3 cycles of chemotherapy have a good prognosis without undergoing radiotherapy.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.